Pegylated liposomal doxorubicin as single-agent treatment of low-grade non-Hodgkin's lymphoma: A phase II multicenter study

Clinical Lymphoma

Volumn 3, Issue 4, 2003, Pages 235-240

  Di Bella, Nicholas J ^a   Khan, Myrna M ^a   Dakhil, Shaker R ^a   Logie, Keith W ^a   Marsland, Thomas A ^a   Weinstein, Ralph E ^a   Mirabel, Mae Y ^a   Asmar, Lina ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

Cardiotoxicity; Chemotherapy; Chronic lymphocytic leukemia; Liposomal doxorubicin; Small lymphocytic leukemia

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; LIPOSOME; MONOCLONAL ANTIBODY; RITUXIMAB;

ADULT; AGE DISTRIBUTION; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; ERYTHEMA; FEMALE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; SURVIVAL TIME;

EID: 0037360626     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2003.n.004     Document Type: Article

References (8)

1. American Cancer Society. Cancer Facts and Figures. 2002 edition. New York, NY. American Cancer Society, Inc.; 2002.
2. Rosenberg S, Berard C, Brown B, Jr, et al. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982; 49:2112-2135.
3. Rosenberg SA. Non-Hodgkin's lymphomas. In: Calabresi P, Schein PS, eds. Medical Oncology, 2nd edition. San Francisco, CA. McGraw-Hill, Inc., 1993:417-433.
4. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JAMA 1958; 53:457-481.
5. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19:3312-3322.
6. Ranson MR, Carmichael J, O'Byrne K, et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997; 10:3185-3191.
7. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast cancer. Cancer 2000; 89:1037-1047.
8. Wigler N, Inbar M, O'Brien M, et al. Reduced cardiac toxicity and comparable efficacy in a phase III trail of pegylated liposomal doxorubicin (Caelyx/Doxil) vs. doxorubicin for first-line treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 2002; 21:45a (Abstract #177).